After speaking to management about these positive developments, we continue to feel that current prices remain underappreciated, especially given how far along in the FDA approval process the company now finds themselves. We also take note that Ergomed has almost 25 physicians who can directly call on clinical sites to aid recruitment and retention.
CEL-SCI obviously believes that interaction on a physician to physician level is what is needed to help physicians increase enrollment in the Multikine study.
"They key to our study is the speed of enrollment," said CEO Kersten. "The CROs we selected are putting $10 million of their own money at stake. This, combined with our own observations in other studies makes us comfortable with their projections for enrollment figures."
Very active CEL-SCI shares broke a down trend recently and are currently trading -54.48% below their 52-week high of $.58, so we see some technical room to the upside at these levels. The market has also seen a -1.85% decrease in the number of shares currently short the stock with approximately five days left to cover.
The complete version of this report by Ray Dirk's Research can be found here:
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
Add to Digg Bookmark with del.icio.us Add to Newsvine
Media Contacts Only:
e-mail: Email Contact
Most Popular Stories
- Accenture Gets 8 Percent Bump in Q1
- Texting With Vodka: Booze and Social Media Can Mix After All
- Lockheed Martin Ends Gifts to Boy Scouts Over Gay Ban
- Mazda Leads the Pack for Fuel Efficiency
- Menendez Pushes for Iran Sanctions
- How to Protect Yourself After Target Data Breach
- Debt Ceiling Looms Again as Deadline Approaches
- Stripped-Down Defense Bill Creates Winners, Losers
- Senate Nears Approval of Defense Bill
- Deportation Threat Looms Larger Than Citizenship Among Hispanics